Improving the knowledge and science of our pharmaceutical medicinal cannabis
Studies Currently Open For Recruitment
What is this study?
We are conducting a study to assess the safety and efficacy of our standardised CBD-rich medicinal cannabis in managing chronic conditions, including chronic pain, anxiety disorders, autism, PTSD, insomnia and epilepsy, that haven’t responded well to standard treatment options.
Who can participate?
Patients who are prescribed Bod medicinal cannabis, with the approval of the Therapeutic Goods Administration (TGA), and meet the eligibility criteria will be able to participate in this important observational study.
How can I participate?
The study is being conducted through numerous trusted and ethics-approved medical clinics with doctors who are experts in cannabis medicines. Contact one of the clinics and ask about the Bod observational study to being assessing eligibility. A list of approved clinics can be found below.
What does participation involve?
Participation in the study involves periodically completing online questionnaires on health outcomes and response to the medication using the study app or website for the duration of the study (up to 12 months).
Patients who participate will receive their first two bottles of medicine that are prescribed as complementary, and the medicines prescribed for the remainder of the study (up to 12 months) will be discounted. Pharmacy dispensing costs (typically no more than $30) and clinic consultation fees apply.
This ‘real-world’ data collected in this study will help gather evidence on the use of medicinal cannabis to help doctors better understand the use of medicinal cannabis for a number of conditions and improve patient access.
To participate in the study, contact one of the ethics-approved clinics listed below by clicking on their icon and mention this study to assess eligibility for consultation. We have also created an information leaflet and convenient referral letter that can be downloaded by clicking the download button above.
|Clinic||Phone number||Location||National Telehealth Consultation||In-Clinic consultation|
|Ananda Clinics||02 5624 5024||Byron Bay, NSW|
|Australian Access Clinics||02 9098 9128||Mascot , NSW|
|Bellingen Healing Centre||02 6655 0000||Bellingen, NSW|
|Bourke Street Clinic||02 9332 0400||Surry Hills, NSW|
|CA Clinics||1300 991 477||Sydney, NSW|
|CDA Clinic||1300 232 362||Brisbane and Gold Coast, Qld|
|Compass Lifestyle Clinics||02 8820 0811||Baulkham Hills, NSW|
|Invitation to Health||02 4322 0700||Wyoming, NSW|
|Tetra Health||1800 861 099||Sydney, NSW|
This study was approved by the Belberry Human Ethics committee and is registered on ANZCTR. More information about the study, including exclusion and inclusion criteria can be found on the ANZCTR or by contacting us.
Clinical Trial For Insomnia (Phase 1 / Phase 2) – Australia
A pilot study investigating the efficacy of one of Bod’s medicinal cannabis product for its potential in treating insomnia in a landmark sleep study is being conducted at the Woolcock Institute of Medical Research, under direction from Professor Ron Grunstein, in partnership with the Lambert Initiative.
Patients who would like to participate can email the trial coordinator (Anastasia) or check their eligibility at:
Clinical trial for Tourette’s syndrome (Phase 2) – Australia
Bod’s medicinal cannabis product is being investigated as a potential treatment option for Tourette’s syndrome. The study is being conducted by the Wesley Medical Research in Brisbane, with the support of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.
Patients can find more information on the study or register their interest to participate here:
Project Twenty21 – UK
Project Twenty21 aims to create the largest body of evidence for the efficacy of medicinal cannabis. The initiative will use collated data to support policy makers as they review medicinal cannabis availability, and affordability for patients who would benefit from its use. The project will assist prescribers operating in private practice and advance the potential for UK Government Health (NHS) funding. Project Twenty21 will focus on these conditions:
- Anxiety Disorder
- Chronic Pain
- Multiple Sclerosis (MS)
- Post-Traumatic Stress Disorder (PTSD)
- Substance Use Disorder (as a harm reduction strategy)
- Tourette’s Syndrome
Bod Medicinal Cannabis will be included in this landmark study. If you are in the UK and meet the selection criteria you may be eligible in participating.
Gold Coast University Hospital in Australia is conducting a randomised double-blind, single-centre phase 3 trial is to assess the safety, tolerability and efficacy of a Bod pharmaceutical-grade medicinal cannabis in improving the symptoms and slowing the progression of disease in motor neurone disease (MND) patients, also referred to as Amyotrophic lateral sclerosis (ALS). The study team aims to treat thirty (30) patients over a period of six months to evaluate the potential protective mechanisms of cannabis that could help to delay disease progression.
If you have MND you may be able to participate in this trial at the Gold Coast University Hospital, QLD. The study will include comprehensive neurological and diagnostic assessments at no cost to approved participants. Participants will be assigned by chance (a process called randomisation) to receive either medicinal cannabis or placebo. Treatment will continue for 180 days (6 months), with a commitment to taking the medication every day for this period. You will be seen every 3 months in the research clinic, located at the Gold Coast University Hospital. Monthly telephone calls will occur between these clinic visits. This study will not interfere with any other medication you are taking at the time and you will remain under the care of your primary physicians.
To be considered for inclusion in the study you need to:
- Have a probable or definite diagnosis of MND
- Be between the ages of 25 and 75
- Have symptom onset within the past two years
Exclusion criteria and further details on this research, ‘Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease (EMERALD Study)’, can be found on the Australian and New Zealand Clinical Trials Registry (ANZCTR) site, here.
This research will provide preliminary data on whether medicinal cannabis has an effect on the progression of MND. Research is ongoing and there are currently no completed studies that have looked at cannabis as a treatment to delay MND progression and prolong survival in humans.
To register your interest please email study co-ordinator, Mr Berzenn Urbi, at Berzenn.Urbi@health.qld.gov.au
Bod Australia has invested in a phase 1 clinical study that assessed the safety, tolerability and pharmacokinetics of the MediCabilis™ 5% CBD (LINNEA 315CSE™) full-spectrum oil and innovation wafer delivery technology. The research was conducted and completed at Nucleus Network, and published in the prestigious British Journal of Clinical Pharmacology.
- 2019. A Novel Standardized Cannabis sativa L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions
- 2019. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury.
Exploring Potential Clinical Applications
Research of the Bod full-spectrum product (50mg CBD/mL) is currently underway with the University of South Australia, School of Pharmacy and Medical Sciences.
The study will provide valuable information for clinical practice, future research and assist in ongoing product development.